NCT02560337View on ClinicalTrials.gov

Cabazitaxel in Patients With Recurrent Ovarian Cancer After Failure of Standard Therapy.

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

December 5, 2018

Study Completion Date

June 1, 2019

Conditions
Ovarian Cancer
Interventions
DRUG

Cabazitaxel

Trial Locations (1)

Unknown

Vejle Hospital, Department of Oncology, Vejle

All Listed Sponsors
lead

Vejle Hospital

OTHER

NCT02560337 - Cabazitaxel in Patients With Recurrent Ovarian Cancer After Failure of Standard Therapy. | Biotech Hunter | Biotech Hunter